1. Membrane Transporter/Ion Channel
  2. NKCC
  3. Bumetanide sodium

Bumetanide sodium  (Synonyms: Ro 10-6338 sodium; PF 1593 sodium)

Art. -Nr.: HY-17468A
Handling Instructions Technical Support

Bumetanide sodium, a highly potent loop diuretic, is a Na+-K+-Cl+ cotransporter (NKCC) blocker. Bumetanide sodium is a selective NKCC1 inhibitor, and also inhibits NKCC2, with IC50s of 0.68 and 4.0 μM for hNKCC1A and hNKCC2A, respectively.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr. : 28434-74-4

Größe Verfügbarkeit
50 mg   Angebot einholen  
100 mg   Angebot einholen  
250 mg   Angebot einholen  

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of Bumetanide sodium:

Other Forms of Bumetanide sodium:

Top Publications Citing Use of Products

    Bumetanide sodium purchased from MedChemExpress. Usage Cited in: EMBO J. 2025 Mar;44(5):1540-1562.  [Abstract]

    NKCC1-mediated Cl- influx was inhibited by furosemide, Bumetanide, and torsemide applied externally to the cells at 100 μM concentration.

    Bumetanide sodium purchased from MedChemExpress. Usage Cited in: J Physiol. 2025 May;603(9):2619-2632.  [Abstract]

    Representative short-circuit current traces (left) and summary graphs (right) from epithelia kept in control conditions, treated with IL-4 or treated with IL-17A/TNF-α. During recordings, CFTRinh-172 (apical, 10 µM) and Bumetanide (basolateral, 100 µM) were added sequentially after stimulation of CFTR with CPT-cAMP. Dotted and dashed lines indicate the baseline for cAMP-activated current and zero current level, as in previous legends. The graphs report the fraction of the cAMP-activated current blocked by CFTRinh-172 (I-172), bumetanide alone (bum) or both compounds together (tot).

    Bumetanide sodium purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2022 Jun 21;19(1):163.  [Abstract]

    Representative images of immunofluorescence staining for p-NKCC1 and p-NKCC1-positive cell statistics of the choroid plexus at 3 days following Bumetanide treatment (6 rats/group, Welch's two-tailed unpaired t-test). Bar = 50 μm.

    Bumetanide sodium purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2022 Jun 21;19(1):163.  [Abstract]

    Western blot analysis of p-NKCC1 and NLRP3 in the choroid plexus at 3 days after Bumetanide treatment.

    Bumetanide sodium purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2022 Jun 21;19(1):163.  [Abstract]

    CSF secretion rates after Bumetanide treatment (6-8 rats/group, Welch's two-tailed unpaired t-test).
    • Biologische Aktivität

    • Reinheit & Dokumentation

    • Verweise

    • Kundenbewertung

    Beschreibung

    Bumetanide sodium, a highly potent loop diuretic, is a Na+-K+-Cl+ cotransporter (NKCC) blocker. Bumetanide sodium is a selective NKCC1 inhibitor, and also inhibits NKCC2, with IC50s of 0.68 and 4.0 μM for hNKCC1A and hNKCC2A, respectively[1][2].

    In Vitro

    Bumetanide sodium has inhibitory effects for the two major human splice variants of NKCCs, hNKCC1A and hNKCC2A [1].
    Bumetanide sodium (0.03-100 μM; 5 minutes) inhibits the 86Rb+ uptake in NKCC1A-expressing oocytes in a dose-dependent manner[1].
    Bumetanide sodium inhibits NKCC2 isoform B in HEK-293 cells with an IC50 value of 0.54 μM[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    In Vivo

    Bumetanide sodium (7.6-30.4 mg/kg; i.v.) attenuates the decrease in apparent diffusion coefficients (ADC) ratios for both cortex and striatum (by 40-67%), indicating reduced edema formation[3].
    Bumetanide sodium also reduces infarct size[3].
    Bumetanide sodium shows different half-lives of 21.4 min, 53.8 min and 137 min following 2 mg/kg, 8 mg/kg and 20 mg/kg intravenous injection, respectively, in rats[4].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Klinische Studie
    Molekulargewicht

    386.40

    Formel

    C17H19N2NaO5S

    CAS. Nr.
    SMILES

    O=C(O[Na])C1=CC(NCCCC)=C(OC2=CC=CC=C2)C(S(=O)(N)=O)=C1

    Versand

    Room temperature in continental US; may vary elsewhere.

    Speicherung

    Please store the product under the recommended conditions in the Certificate of Analysis.

    Reinheit & Dokumentation
    Verweise
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    • Molaritätsrechner

    • Verdünnungsrechner

    Die Formel zur Berechnung von Molaritäten

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)

    Diese Gleichung wird häufig abgekürzt als: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Ihre kürzlich angesehenen Produkte:

    Online-Anfrage

    Your information is safe with us. * Required Fields.

    Produktname

     

    Requested Quantity *

    Name des Antragstellers *

     

    Anrede

    E-Mail-Addresse *

     

    Telefonnummer *

    Department

     

    Name der Organisation *

    City

    Bundesland

    Country or Region *

         

    Bemerkungen

    Massenanfrage

    Inquiry Information

    Produktname:
    Bumetanide sodium
    Art. -Nr.:
    HY-17468A
    Menge:
    MCE Japan Authorized Agent: